Telus PeptidesCardiogen
Bioregulators Research compound (not approved for human use)
Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Arg) · also known as AEDR, Ala-Glu-Asp-Arg
For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.
Cardiogen is one of the tissue-labelled short peptides developed by the Khavinson group, linked in their publications to cardiac muscle and fibroblast biology. Its literature is small, mostly from one research group, and no clinical dosing trial defines an amount or schedule.
Commonly reported dosing (20 mg vial)
| Phase | Dose | Volume | U-100 units |
|---|---|---|---|
| Starting | 200 mcg | 0.03 mL | 3 |
| Standard | 300 mcg | 0.045 mL | 4.5 |
| Higher | 500 mcg | 0.075 mL | 7.5 |
Commonly reported reconstitution steps
- Vials are usually brought to room temperature (about 15-20 minutes) first.
- 3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
- The vial is swirled gently until clear, not shaken.
- This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.
Storage
Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.
After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.
How it works
Hypothesized to interact with histones and DNA and to modulate genes involved in cardiomyocyte survival and fibroblast proliferation; this is a proposed mechanism from cell and animal work.
Researched for
- Studied in cell and animal models for effects on cardiomyocytes and cardiac fibroblasts.
- Binding to histone proteins examined in vitro together with other short peptides.
- Described in reviews as a regulator of cardiovascular-system gene expression.
Notes
- Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
- Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
- The dose figures above could only be cross-checked against a summary of the reference chart; regard them as approximate community conventions.
- Not FDA-approved.
Sources
Related
Vesugen
Synthetic tripeptide bioregulator (Lys-Glu-Asp)Vesugen is a three-residue peptide (lysine, glutamate, aspartate) from the Khavinson family, associated with blood vessels and the cardiovascular system.
Bronchogen
Synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Leu)Bronchogen is a four-residue peptide (alanine, glutamate, aspartate, leucine) studied by the Khavinson group as a regulator of airway tissue.
Pinealon
Synthetic tripeptide bioregulator (Glu-Asp-Arg)Pinealon is a three-residue peptide (glutamate, aspartate, arginine) developed by the Khavinson group as a brain-oriented bioregulator.
Epitalon
Synthetic tetrapeptide (Ala-Glu-Asp-Gly)Epitalon is a four-amino-acid synthetic peptide modelled on a pineal gland extract and studied for telomerase activity and aging biology.
Cartalax
Synthetic tripeptide bioregulator (Ala-Glu-Asp)Cartalax is a three-residue peptide (alanine, glutamate, aspartate) studied by the Khavinson group in connection with cartilage and connective tissue.
Chonluten
Synthetic tripeptide bioregulator (Glu-Asp-Gly)Chonluten is a three-residue peptide (glutamate, aspartate, glycine) described by the Khavinson group in connection with airway and lung tissue.